Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.